News on drug screening, clinical trials, companion diagnostics, immunotherapy, & personalized therapies in genetics, genomics, and molecular diagnostics.
The firm now intends to set up an internal laboratory to experiment with different compounds, while building out its team.
The investment bank began coverage with an Outperform rating, noting that Horizon's recent acquisition of Dharmacon is highly complementary and synergistic.
Thermo Fisher has acquired the contract development and manufacturing organization for $35 per share in cash.
Researchers from Hong Kong imputed transcriptomes from GWAS data and compared them to drug-induced gene expression profiles.
The SPRING trial is exploring a three-drug strategy, starting with Ibrance, Inlyta, and Bavencio, and will validate a biomarker algorithm for predicting responders.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.